Sugi Predict

Sugi Predict / Compounds / SCHEMBL2769466

SCHEMBL2769466

SCHEMBL2769466

CC(=O)OCC(O)O[C@@H](CCO)COC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DUT P33316 2/20 0.42
▸ TK1 P04183 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.34
▸ CYP2C9 P11712 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ CTSK P43235 2/20 0.32
▸ LMNA P02545 1/20 0.32
▸ ACSS2 Q9NR19 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ KIF11 P52732 1/20 0.31
▸ ELANE P08246 1/20 0.31
▸ PLA2G2A P14555 2/20 0.31
▸ PLA2G10 O15496 1/20 0.31
▸ PLA2G1B P04054 1/20 0.31
▸ PLA2G5 P39877 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13377619 0.81 DUT (0.41) DUTTK1ALDH1A1CYP2C9ALOX15
SCHEMBL2771065 0.79 L3MBTL1 (0.37) ALDH1A1KIF11
SCHEMBL4186770 0.72 DUT (0.44) DUTTK1ALDH1A1CYP2C9ALOX15
SCHEMBL4186763 0.72 DUT (0.44) DUTTK1ALDH1A1CYP2C9ALOX15
SCHEMBL26439425 0.71 PLA2G2A (0.42) DUTTK1CYP2C9ALOX15TSHR
SCHEMBL4186683 0.71 TK1 (0.50) DUTTK1ALDH1A1CYP2C9ALOX15
SCHEMBL4186681 0.71 TK1 (0.50) DUTTK1ALDH1A1CYP2C9ALOX15
SCHEMBL15928761 0.70 DUT (0.44) DUTTK1CYP2C9ALOX15TSHR
SCHEMBL8585846 0.69 TDP1 (0.54) DUTTK1ALDH1A1ACSS2KCNH2
SCHEMBL10772460 0.68 TK1 (0.54) DUTTK1ALDH1A1CYP2C9ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363640-B1 NUCLEIC ACID DERIVATIVES BIO RAD LABORATORIES (US) 2010-04-28 — — EP disclosed
US-7683164-B2 Nucleic acid derivatives BIO-RAD LABORATORIES INC. (US) 2010-03-23 — — US disclosed
US-20090005334-A1 cyclic moieties which enable the formation of stable hybrids with natural nucleic acids and can therefore be efficiently used in a wide variety of applications and, in particular, in antisense therapy BIO-RAD LABORATORIES INC. (US) 2009-01-01 — — US disclosed
US-7348148-B2 Nucleic acid derivatives BIO-RAD LABORATORIES INC. (US) 2008-03-25 — — US disclosed
US-20060148751-A1 Nucleic acid derivatives BIO-RAD LABORATORIES INC. (US) 2006-07-06 — — US disclosed
US-7034131-B2 Nucleic acid derivatives BIO-RAD LABORATORIES INC. (US) 2006-04-25 — — US disclosed
US-20030191074-A1 Nucleic acid derivatives BIO-RAD LABORATORIES INC. 2003-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191074-A1 Nucleic acid derivatives NSUN2, POLRMT, ADAR DUT 41/4885TK1 157/4885ALDH1A1 2425/4885
US-20060148751-A1 Nucleic acid derivatives NSUN2, POLRMT, ADAR DUT 38/4885TK1 144/4885ALDH1A1 2503/4885
US-20090005334-A1 cyclic moieties which enable the formation of stable hybrids with natural nucleic acids and can therefore be efficiently used in a wide variety of applications and, in particular, in antisense therapy POLRMT, NSUN2, RNGTT DUT 57/4885TK1 92/4885ALDH1A1 2920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.